Trusted by 10,000+ Scientists since 2006

Trk Receptors

Inhibitory Selectivity
Catalog No.Inhibitor Name TrkATrkBTrkCTrk receptorOther
Insulin Receptor,IGF-1R,Met
A16259Sitravatinib (MGCD516)
A15801Entrectinib (RXDX-101)
A10053Tyrphostin AG 879
A10715Danusertib (PHA-739358)
Aurora A, Abl, RET, FGFR1, Aurora C, Aurora B
A15974Larotrectinib (LOXO-101) sulfate

1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

14 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A15494 SALE


TrkB agonist
LM22A-4 is a potent tropomyosin-related kinase B (TrkB) agonist (IC50 = 47 nM).

LOXO-101 sulfate

TRK inhibitor
LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.

GW 441756

TrkA inhibitor
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM; little activity to c-Raf1 and CDK2.


TrkB agonist
7,8-Dihydroxyflavone, a selective tyrosine kinase receptor B (neurotrophic factor/tropomyosin-receptor-kinase B; TrkB) agonist, may be used to help identify and differentiate the physiological effects and cell signaling pathways mediated by TrkB activation, such as those involving neuroprotection, memory, vasorelaxation and hypertension.

LOXO-101 (ARRY-470, Larotrectinib)

TRK inhibitor
LOXO-101 is an orally bioavailable, potent, ATP-competitive inhibitor of TRKA, TRKB, and TRKC.
A13877 SALE


TrkB inhibitor
ANA-12 is a TrkB receptor antagonist that demonstrates a 2-site mode of action, preventing activation by BDNF non-competitively.


TRK, ROS1, ALK inhibitor
Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity.
A10715 SALE

Danusertib (PHA-739358)

Aurora inhibitor
Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2


VGF-derived peptide
TLQP 21, VGF-derived peptide; spans residues 556-576 of the precursor sequence.
A13730 SALE

GNF 5837

TRK inhibitor
GNF-5837 is a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF.

AZ 23

TrkA inhibitor
AZ 23 is a potent and selective tyrosine kinase Trk inhibitor with IC50 to 2 and 8 nM for TrkA and TrkB respectively
A10053 SALE

Tyrphostin AG 879

HER2 inhibitor
Tyrphostin AG 879 is an inhibitor of the tyrosine kinase activity of nerve growth factor (NGF) TrkA.
A11059 SALE


IGF-1R inhibitor
BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.


RTK inhibitor
Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth.

14 Item(s)

per page

Set Descending Direction